BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer.
The Independent Data Monitoring Committee recommended terminating the ongoing Phase 3 AdvanTIG-302 trial (NCT04746924) based on its findings as part of a pre-planned futility analysis. The overall efficacy and safety data assessment suggested that the study was unlikely to meet the primary endpoint of overall survival. No new safety signals were observed. After thorough deliberation, the Company has made the decision to terminate the trial.
“We evaluate our clinical programs to focus our resources on the most promising clinically differentiated candidates while thoughtfully de-prioritizing others. Our commitment remains steadfast: to discover and develop innovative treatments that are more affordable and accessible to cancer patients worldwide,” said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. “We thank the investigators, their patients, and support staff whose participation and dedication made this research possible.”
Results from this study will be shared at a later date to help advance science and the understanding of anti-TIGIT activity.
About BeiGene
BeiGene, which plans to change its name to BeOne Medicines Ltd., is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 11,000 colleagues spans six continents. To learn more about BeiGene, please visit www.beigene.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the ability of results from the AdvanTIG-302 trial to help advance science and the understanding of anti-TIGIT activity; and BeiGene’s plans, commitments, aspirations, and goals under the heading “About BeiGene.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeiGene’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products;BeiGene’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.
To access BeiGene media resources, please visit ourNews & Mediasite.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250403796676/en/
Contacts
Investor Contact
Liza Heapes
+1 857-302-5663
ir@beigene.com
Media Contact
Kyle Blankenship
+1 667-351-5176
media@beigene.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Western Union Offers Zero-Fee International Money Transfers to Myanmar4.4.2025 04:00:00 EEST | Press release
In response to the devastating earthquake that recently struck Myanmar, Western Union today announced that it is offering consumers around the world zero-fee international money transfers1 to the country. Effective immediately until midnight, 00:00 Myanmar Standard Time on 10 April 2025, individuals can send funds to Myanmar via WesternUnion.com or the Western Union mobile app, ensuring families can provide crucial support to their loved ones during this time of urgent need. Western Union remains committed to providing support during times of crisis, offering zero-fee transfers whenever possible to help communities in need. Money transfers sent to Myanmar will be: Available for payout into bank accounts. Available for payout into select mobile wallets Available for payouts incash at Agent locations2 “Our thoughts are with the people of Myanmar during this incredibly difficult time,” said Atish Shrestha, Western Union’s Regional Director for Indochina, South Korea and Taiwan, Western Un
Clean Tech Leader Aymium Defeats Stora Enso at European Patent Office Boards of Appeal4.4.2025 01:07:00 EEST | Press release
Cleantech leader Aymium defeated a challenge by Stora Enso to one of Aymium's patents (European Patent EP2697185) that provides exclusive rights to produce, sell and use bio-based materials for renewable battery applications. In its written opinion, the Boards of Appeal of the European Patent Office found Stora Enso's arguments brought before the board “not convincing” and agreed that a clarifying amendment to the claims did not extend the scope of protection of the patent. The ruling further affirms Aymium's position as the global leader in biocarbon materials for battery applications. Beyond the present ruling, Aymium owns a portfolio of more than 600 patents relating to biocarbon materials, compositions and manufacturing methods, including many specifically relevant to battery materials, and is the dominant global innovator regarding biocarbon materials. The ruling, combined with Aymium's massive patent portfolio, calls into question the ability of Stora Enso to produce bio-based ba
Esri Helps Bring Up-to-Date Road Closure Information To Consumer Mapping Apps4.4.2025 00:24:00 EEST | Press release
Esri, the global leader in GIS technology and location intelligence, has enhanced its popular Community Maps Program to make sharing of road closures much easier with the Road Closures solution. This new solution in Esri's ArcGIS, the leading and most comprehensive geospatial platform, bridges the gap between government agencies managing timely road updates and the public, who rely on mapping apps for real-time navigation. Thousands of Esri's ArcGIS software users — including state and local governments and national mapping agencies — create and share authoritative, accurate road data through the Esri Community Maps Program, and now they can share live road closure data as well. Esri ArcGIS users can now easily share road closure updates directly with consumer mapping providers including Apple Maps and TomTom, so they can update their maps with this important information. "Through the Esri Community Maps Program, we've been assembling authoritative data about city infrastructure from t
smartTrade Announces Strategic Investment from TA alongside CEO and Management3.4.2025 19:37:00 EEST | Press release
smartTrade Technologies (“smartTrade”), a leading global provider of multi-asset electronic trading and payments platforms, today announced a strategic investment from TA Associates (“TA”), a leading global private equity firm. David Vincent, CEO and Co-Founder of smartTrade, and the broader management team, would invest alongside TA at closing, reinforcing their shared commitment to the company’s future. Headquartered in Aix-en-Provence, France, with subsidiaries in London, Paris, Geneva, New York, Toronto, Tokyo and Singapore, smartTrade empowers customers to grow their electronic trading and payments business through secure, cost-efficient and technologically advanced end-to-end SaaS solutions. TA’s investment would support continued product innovation, geographic expansion and scalable growth, with a particular emphasis on AI-driven solutions and deployment flexibility. Upon completion of the transaction, Hg, a leading investor in European and transatlantic software and services bu
Barilla Ranks as the First Food Company in the World for Reputation in the 2025 Global RepTrak ® 1003.4.2025 18:59:00 EEST | Press release
Barilla Group is proud to announce its rise in the Global RepTrak® 100 rankings, emerging as the leading company in the food sector two years running. The company has secured the 25th position worldwide, moving up four spots compared to 2024, where it held the 29th position. This result, achieved thanks to the efforts of the Group’s people worldwide, reflects its continued focus on the quality of its products and services, inclusion, innovation, and willingness to bring people together through good food. With a presence in over 100 countries and 30 production sites (15 in Italy and 15 abroad), Barilla Group produces more than 2 million tons of products each year. Since 2010, it has reformulated nearly 500 products to improve their nutritional profile, reducing fats, saturated fats, salt, and sugar, or increasing fiber content. Aligned with its commitment to fostering inclusivity, in France the company has achieved a 100% score on the Professional Gender Equality Index1 this year, an in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom